Radiopharm Theranostics (ASX:RAD) and BAMF Health Partner on Brain Metastasis Imaging Study

October 21, 2024 12:04 PM AEDT | By Aditi Sarkar

Radiopharm Theranostics (ASX:RAD) and BAMF Health Partner on Brain Metastasis Imaging Study — Image source: Company Update

Recent News

Heavy Rare Earths Secures Key Uranium Projects from Havilah Resources

Delta Future Industry Summit 2024 Leads the Charge in Unlocking AI's P...

Manulife Celebrates 25th Anniversary of Initial Public Offering with C...

The China-Malaysia youth exchange delegation visited Jiangxi

Highlights

Radiopharm has collaborated with BAMF Health to advance the clinical program for RAD 101 targeting brain metastasis.

BAMF Health will be the first clinical site to open for patient dosing in Radiopharm’s Phase 2b imaging study of 18F-RAD 101.

Patient enrolment is expected to commence in the last quarter of 2024.

Radiopharm Theranostics Limited (ASX:RAD) is trading higher on the ASX today, with an increase of over 7%, following its announcement of a strategic partnership with BAMF Health, a company specialising in molecular imaging and theranostics. The collaboration is crucial in advancing Radiopharm’s RAD 101 clinical program.

BAMF Health will manufacture 18F-RAD 101, Radiopharm’s proprietary F18-tagged radiotracer designed to detect and characterise brain metastasis. As part of this partnership, BAMF Health is set to be the first clinical site to open for patient dosing in Radiopharm’s Phase 2b imaging study of 18F-RAD 101.

RAD 101 is a novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that catalyses fatty acid synthesis. FASN is overexpressed in many solid tumours, including cerebral metastasis.

Commenting on the partnership, Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics Ltd., said, “Disruption of FASN activity allows for the accurate detection of cancer cells, representing a strongly viable target for the imaging of brain metastases. Our partnership with BAMF Health is instrumental in progressing our RAD 101 clinical program. With BAMF Health’s leadership in manufacturing and clinical trial conduct, we collectively pave the way to bringing innovative radiopharmaceuticals to oncology patients across the globe.”

The share price of RAD was AU$ 0.030 at the time of writing on 21 October 2024.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.